anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prodn. of human follicle-stimulating hormone(hFSH) comprises (a) transplanting human cells capable of producing hFSH into any warm- blooded animal other than a human; (b) feeding the aninal to cause the cells to multiply; (c) extracting and disaggregating the grown cells; (d) culturing the human cells in a nutrient medium in the presense of hFSH inducer; and (e) harvesting hFSH. The human cells are pref. hybrids abtd. by cellular fusion of a human lymphoblastoid line, with human cells capable of producing hFSH, such as human basophile adenoma cells. Suitable hFSH inducers include amino acids, mineral salts and a hormone. hFSH has speromatozoa formation- promoting action at testeo. It promotes growth, maturity of follicles and productive secretion of esterogen at ovarium.
This intensive trauma focused therapy is comprised of 16 sessions of therapy with two therapists including three long sessions of between 6 to 8 hours followed by an overnight stay and then 3 weekly integration sessions. The therapy is modeled on components of Somatic Experiencing, Acceptance and Commitment Therapy and the psychedelic assisted therapy protocols.
Administer the recommended pediatric dose of 52 mg/m2 as an intravenous infusion over 2 hours daily for 5 consecutive days.

  * Repeat treatment cycles following recovery or return to baseline organ function, approximately every 2 to 6 weeks. Base dosage on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, do not administer other medications through the same intravenous line. Administer subsequent cycles no sooner than 14 days from the starting day of the previous cycle and provided the patient's ANC is ≥0.75 × 109/L.
  * Provide supportive care, such as intravenous fluids, antihyperuricemic treatment, and alkalinize urine throughout the 5 days of Clolar administration to reduce the effects of tumor lysis and other adverse reactions.
  * Discontinue Clolar if hypotension develops during the 5 days of administration.
  * Monitor renal and hepatic function during the 5 days of Clolar administration [see Warnings and Precautions (5.7, 5.8)].
  * Monitor patients taking medications known to affect blood pressure. Monitor cardiac function during administration of Clolar.
Carcinogenesis and Mutagenesis: Doxazosin mesylate was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 40 mg/kg/day or 120 mg/kg/day, respectively. Systemic drug exposures, as measured by AUC, were approximately 34-fold in rats and 16-fold in mice above the exposures at the maximum human recommended dose (MHRD) of 8 mg CARDURA XL.

Doxazosin base was not mutagenic in the in vitro bacterial Ames assays, the chromosomal aberration assay in human lymphocytes, or the mouse lymphoma assay. Doxazosin was not clastogenic in the in vivo mouse micronucleus assay. Doxazosin mesylate has not been evaluated for genotoxicity.

Fertility in Males: Studies in rats after oral administration of doxazosin base showed reduced fertility in males, which was reversible after two weeks of treatment termination at doxazosin base exposure of 13-fold above the human exposure (AUC) at the MHRD of 8 mg CARDURA XL. There have been no reports of any effects of doxazosin on male fertility in humans.
PROBLEM: The placental membranes are a key barrier to fetal and uterine infection. Inflammation of the membranes, diagnosed as maternal inflammatory response (MIR) or alternatively as acute chorioamnionitis, is associated with adverse maternal-fetal outcomes. MIR is staged 1-3, with higher stages indicating more hazardous inflammation. However, the diagnosis relies upon subjective evaluation and has not been deeply characterized. The goal of this work is to develop a cell classifier for eight placental membrane cells and quantitatively characterize MIR1-2.
METHOD OF STUDY: Hematoxylin and eosin (H&E)-stained placental membrane slides were digitized. A convolutional neural network was trained on a dataset of hand-annotated and machine learning-identified cells. Overall cell class-level metrics were calculated. The model was applied to 20 control, 20 MIR1, and 23 MIR2 placental membrane cases. MIR cell composition and neutrophil distribution were assessed via density and Ripley's cross K-function. Clinical data were compared to neutrophil density and distribution.
RESULTS: The classification model achieved a test-set accuracy of 0.845, with high precision and recall for amniocytes, decidual cells, endothelial cells, and trophoblasts. Using this model to classify 53 073 cells from healthy and MIR1-2 placental membranes, we found that (1) MIR1-2 have higher neutrophil density and fewer decidual cells and trophoblasts, (2) Neutrophils colocalize heavily around decidual cells in healthy placental membranes and around trophoblasts in MIR1, (3) Neutrophil density impacts distribution in MIR, and (4) Neutrophil metrics correlate with features of clinical chorioamnionitis.
CONCLUSIONS: This paper introduces cell classification into the placental membranes and quantifies cell composition and neutrophil spatial distributions in MIR.
Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
The study will enroll approximately 250 participants, \~100 at 2 sites in Canada and \~100 at 2 sites in Africa. Overall \~200 participants will receive the study vaccine and 50 will receive a placebo . Sequential enrollment of five study cohorts will occur over time at each study site according to CD4 T-cell counts: Group 1 will include adult subjects with CD4 ≥ 500 cells/mm3, Group 2 CD4 \> 350 and \< 500 cells/mm3, Group 3 CD4 ≥ 200 and ≤ 350 cells/mm3, Group 4 adolescents CD4 ≥ 200 cells/mm3, and Group 5 adults and adolescents CD4 ≥ 200 cells/mm3. Enrolment and vaccine administration will begin with the group with the highest CD4 count. When the D42 post-vaccination period is completed for all subjects in Group 1, and the Data Safety Monitoring Board (DSMB) has reviewed the safety data and determined that there are no concerns, enrolment and vaccination of the next CD4 cohort may begin. Similarly, when the D42 safety data for Group 2 has been reviewed/approved by the DSMB, enrolment and vaccination of participants in Group 3 may begin. Adolescents 13-17 years of age (inclusive) with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adults with CD4 ≥ 200. Adolescents 13-17 years of age (inclusive) and adults with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adolescents with CD4 ≥ 200.Within each group, participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the study vaccine or the placebo in a ratio of 4 to 1 (160:40). Participants will complete memory aids for 42 days following vaccination.

Specific procedures to be performed during the trial, as well as their prescribed times and associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each procedure are provided in Section 7.0 - Trial Procedures.

This trial will use an adaptive design based on pre-specified criteria, using an independent, external DSMB to monitor safety and immunogenicity. There will be 3 formal safety analyses performed by the DSMB. Data for at least 75% of participants must be available for each analysis. The first safety analysis will be conducted when the first group (CD4 ≥ 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The second safety analysis will be conducted when the second group (CD4 \> 350 and \< 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The third safety analysis will be conducted when the third group (Adults CD4 ≥ 200 and ≤ 350 cells/mm3) will have completed 42 days of follow-up post vaccination. The fourth safety analysis will be conducted when the fourth group (Adolescents CD4 ≥ 200) will have completed 42 days of follow-up post vaccination.

Results of the safety analysis will be reviewed by the DSMB, which will make recommendations to the Sponsor to continue, modify or end the trial according to the plan described briefly in Section 2.2 - Trial Diagram and in detail in Section 8.0 - Statistical Analysis Plan. In case of an outbreak of Ebola Zaire the DSMB may recommend to vaccinate subjects randomized to receive placebo with V920 provided at least 84 days of SAE follow-up is conducted.
1. Use of a botulinum neurotoxin from Clostridium botulinum of type A, B, C, D, E, F or G or a mixture of two or more such neurotoxin, characterized in that the neurotoxin or mixture of neurotoxin is free of the complexing proteins which naturally form complexes with botulinum neurotoxin, for the manufacture of a pharmaceutical for cosmetic treatment or treatment of dystonia or disorders of the nervous system in a human or animal subject already exhibiting neutralizing antibodies against such botulinum neurotoxin complexes. 2. Use as claimed in claim 1 characterized in that said subject exhibits neutralizing antibodies against a complex of Clostridium botulinum type A or B or a complex of Clostridium botulinum type A and type B. 3. Use as claimed in claim 1 or claim 2 characterized in that said cosmetic treatment is in respect of hyperhidrosis. 4. Use as claimed in any one of claims 1 to 3 characterized in that said cosmetic treatment is in respect of wrinkling. 5. Use as claimed in claim 4 characterized in that said cosmetic treatment is in respect of facial wrinkling. 6. Use as claimed in claim 1 or claim 2 characterized in that said dystonia or disorders of the nervous system are selected from spasmodic torticollis, blepharospasm, spasticities such as footdrop, hemifacial spasms, migraine, low back pain, cervical spine disorders and hypersalivation.
There is no evidence that olipudase alfa-rpcp crosses the human placenta. However, published literature reports that early embryonic exposure to a metabolite of sphingomyelin (ceramide) or the S1P receptor modulator fingolimod can produce exencephaly in chicks and mice, respectively. In animal reproduction studies, exencephaly, a neural tube defect occurring in the first trimester of pregnancy, was observed in mouse fetuses at exposures less than the exposure at the maximum recommended human dose of olipudase alfa-rpcp.

XENPOZYME dosage initiation or escalation, at any time during pregnancy, is not recommended as it may lead to elevated sphingomyelin metabolite levels that may increase the risk of fetal malformations [see Use in Specific Population (8.1), Clinical Pharmacology (12.2)]. The decision to continue or discontinue XENPOZYME maintenance dosing in pregnancy should consider the female's need for XENPOZYME, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal ASMD disease.

Verify the pregnancy status in females of reproductive potential prior to initiating XENPOZYME treatment. Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if XENPOZYME is discontinued [see Use in Specific Populations (8.3)].
The invention discloses a polypeptide compound and a preparation method and application thereof. The polypeptide compound has a structure shown in a formula I. The study shows that the preparation method has the advantages that,the polypeptide compound provided by the invention can obviously improve the spatial learning and memory capacity of Abeta-mediated cognitive impairment mice. In addition, the toxicity of the part of polypeptide compounds related to the invention is lower, and the toxicity is lower in the detection of toxicity of kidney cells (Vero) and the detection of hemolysis (rabbit whole blood). Therefore, the method can be used for preparing medicines with NK cell related immunoregulation function, for treating inflammation related diseases or for diagnosing and treating nervous system diseases. The compounds of the present invention may be used alone or in combination with another one or more other active ingredients to treat, prevent, inhibit or ameliorate a disease or condition, wherein the combination of the agents is safer or more effective than the use of either agent alone.
Diamond Blackfan anemia (DBA) is a constitutional pure red cell aplasia of unknown etiology. There is laboratory evidence for an immune mechanism and most patients respond to corticosteroids. However the relapse and failure rate are high, and corticosteroids are associated with many short and long term side effects. Patients who do not respond or who do not tolerate corticosteriods require lifelong red blood cell transfusion and iron chelation therapy. Allogeneic bone marrow transplantation is an option for those with a related histocompatible donor, but this procedure is associated with high mortality and morbidity. Other therapies have been tried without general success. Occasional responses to either ATG or cyclosporine have been reported, but no study has used both ATG and cyclosporine. In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia.
Subjects randomized to the FNB arm will have an ultrasound-guided femoral nerve single shot block performed preoperatively in the anesthesia block room with 20ml of 0.5% ropivacaine local anesthetic. This will be reduced to 15ml in patients under 60 kg.
BACKGROUND: Surveillance colonoscopy after polyp removal is recommended to prevent subsequent colorectal cancer (CRC). It is known that advanced adenomas have a substantially higher risk than non-advanced ones, but optimal intervals for surveillance remain unclear.
DESIGN: We prospectively followed 156 699 participants who had undergone a colonoscopy from 2007 to 2017 in a large integrated healthcare system. Using multivariable Cox proportional hazards regression we estimated the subsequent risk of CRC and high-risk polyps, respectively, according to index colonoscopy polyps, colonoscopy quality measures, patient characteristics and the use of surveillance colonoscopy.
RESULTS: After a median follow-up of 5.3 years, we documented 309 CRC and 3053 high-risk polyp cases. Compared with participants with no polyps at index colonoscopy, those with high-risk adenomas and high-risk serrated polyps had a consistently higher risk of CRC during follow-up, with the highest risk observed at 3 years after polypectomy (multivariable HR 5.44 (95% CI 3.56 to 8.29) and 8.35 (95% CI 4.20 to 16.59), respectively). Recurrence of high-risk polyps showed a similar risk distribution. The use of surveillance colonoscopy was associated with lower risk of CRC, with an HR of 0.61 (95% CI 0.39 to 0.98) among patients with high-risk polyps and 0.57 (95% CI 0.35 to 0.92) among low-risk polyps. Among 1548 patients who had high-risk polyps at both index and surveillance colonoscopies, 65% had their index polyps in the proximal colon and 30% had index and interval polyps in the same segments.
CONCLUSION: Patients with high-risk polyp findings were at higher risk of subsequent CRC and high-risk polyps and may benefit from early surveillance within 3 years. The subsite distribution of the index and recurrent high-risk polyps suggests the contribution of incomplete resection and missed lesions to the development of interval neoplasia.
A substituted monoethylglycinexylidide or analogue is disclosed. The xylidide or analogue has the structure of Fig. 1 of the attached drawings where M is CH₂NHCH₂CH₃, CH₂CH₂CH₂CH₃ or CH₂OCH₂CH₃, one of Y¹ and Y² is H and the other is a protein or a fluorescein moiety chemically bonded to the glycinexylidide or analogue moiety. Also disclosed is a method for carrying out immunoassays for MEGX, which has the structure of Fig. 3 of the attached drawings. The method for carrying out immunoassays involves using the foregoing compounds as tracers and immunogens.
Overweight and obesity are a burgeoning public health concern, yet only a small minority of smartphone apps that claim to facilitate healthy eating and weight loss incorporate evidence-based principles. Such innovations are important as humans fundamentally cannot accurately estimate portion size. Indeed, portion size estimation errors account for \~50% of the error in self-reported food intake, and data from our laboratory has demonstrated that extensive training results in only modest improvements in portion size estimation accuracy and that portion size estimates remain inaccurate. Our long-term goal is to create simple and accessible interventions that assist individuals with weight control. In particular, we aim to provide easy-to-use phone apps that allow participants to monitor the portion sizes of the foods they consume. These apps guide participants on appropriate portion sizes and provide recommendations of food groups that should be consumed. To that end, we have developed the PortionSize app. We propose to improve the accuracy of portion size measurement, as it is poorly determined by self-report measures. This will occur via the development of the PortionSize smartphone app and this pilot study will test the usability as well as preliminary validity and reliability of the app functionality.
This is a Phase I, open-label, dose-escalation study of bendamustine and lenalidomide (BL) and also bendamustine,lenalidomide, and rituximab (BLR) in relapsed/refractory CLL and relapsed/refractory B-cell lymphomas. Phase I dose escalation will be done independently for the CLL and NHL groups. In addition, the study will be conducted in 2 parts. In part I of the study, the maximum tolerated dose of bendamustine and lenalidomide will be determined independently for the CLL and NHL groups. In part II of the study, CLL and NHL subjects will be enrolled at the MTD of BL determined in Part I for CLL and NHL and all subjects will receive rituximab. Part II of the study will determine the MTD of BLT independently for the NHL and CLL groups.
Patients will be treated superficially at points away from classic acupoints. The points include bilateral "Forearm" \[1 inch lateral to the middle point between HE3 and HE7\] , "Upper arm" \[1 inch lateral to LU 3 \], and "Lower leg" \[0.5 inch dorsal to GB39\]; for head, the non-acupoints include bilateral "Head" \[middle point between GB8 and ST8\], "Forehead" \[middle point between ST8 and GB14\], "Neck" \[middle point between TB16 and SI17\], and "Ear" \[the point on the helix, inferior to the apex\]. The points selected have been used in previous acupuncture studies as sham control. "De qi" is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group.
Shoulder problems are one of the common orthopedic problems. Patients with shoulder problems experience an increase in pain and a decrease in joint movement and functionality. With conventional treatment, patients' symptoms improve. However, the MWM is one of the manual therapy techniques frequently used to reduce pain in musculoskeletal system problems. It is extremely important to evaluate patients' functionality after rehabilitation. Although there are studies comparing the effect of MWM in the literature, studies evaluating patient-specific functionality are also limited.
Objective: Previous studies have shown that the cleavage of Sirt1 contributes to the development of osteoarthritis (OA). In fact, OA was effectively abrogated by the intra-articular (IA) administration of two compounds, one blocking Sirt1 cleavage (CA074me) and the other activating Sirt1 (SRT1720), using a post-traumatically induced model (PTOA) in young female mice. In this study, we attempted to understand if this local treatment is effective in preventing age-associated OA (AOA) progression and symptoms. Design: A group of 17-month-old female C57BL/6J mice were IA administered with CA074me and/or SRT1720 or their combination. Joint histopathological analysis and bone histomorphometry were carried out, with an assessment of knee mechanical hyperalgesia. A serum analysis for NT/CT Sirt1 was carried out along with immunohistochemistry for articular cartilage to detect p16INK4A or γH2A.X. Similarly, meniscal cartilage was monitored for Lef1 and Col1a1 deposition. The data were compared for young female mice subjected to post-traumatic OA (PTOA). Results: Similar to PTOA, combination-treated AOA exhibited improved knee hyperalgesia, yet structural improvements were undetected, corresponding to unchanged NT/CT Sirt1 serum levels. Both AOA and PTOA exhibited unchanged staining for nuclear p16INK4A or γH2A.X and lacked a correlation with OA severity. Contrarily to PTOA, the combination treatment with AOA did not exhibit a local reduction in the Lef1 and Col1 targets. Conclusions: When targeting Sirt1 cleavage, the PTOA and AOA models exhibited a similar pain response to the combination treatment; however, they displayed diverse structural outcomes for joint-related damage, related to Lef1-dependent signaling. Interestingly, nuclear p16INK4A was unaffected in both models, regardless of the treatment's effectiveness. Finally, these findings highlight the variations in the responses between two highly researched OA preclinical models, reflecting OA pathophysiology heterogeneity and variations in gender-related drug-response mechanisms.
Sudden cardiac death (SCD) is a global public health problem. Despite efforts of the scientific community, it is characterized by low survival (<10%). Strategies used to prevent this catastrophic event are divided into those aimed at individual and populational level. Individuals known to be at a high risk for SCD may be treated with medications, implantable cardioverter‑defibrillators, catheter ablation, or temporary defibrillation devices. At the population level, efforts are concentrated on prevention of ischemic heart disease, as it is responsible for over 70% of sudden mortality cases in adults, and on development of resuscitation and early defibrillation programs. Much still needs to be done to improve survival by raising awareness in the population through training initiatives and by optimizing available technologies and making them more accessible.
In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
Labetalol hydrochloride (HCl) is an adrenergic receptor blocking agent that has both selective alpha1-adrenergic and nonselective beta-adrenergic receptor blocking actions in a single substance. 

Labetalol HCl is a racemate chemically designated as 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide monohydrochloride, and it has the following structure:

Labetalol HCl has the empirical formula C19H24N2O3•HCl and a molecular weight of 364.9. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R’ stereoisomer, makes up 25% of racemic labetalol. 

Labetalol HCl is a white or off-white crystalline powder, soluble in water. 

Labetalol Hydrochloride Tablets, USP for oral administration contain 100 mg, 200 mg, or 300 mg of labetalol HCl. Each tablet also contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, pregelatinized starch, purified water, and titanium dioxide. Labetalol HCl Tablets, USP 100 mg also contain synthetic red iron oxide and synthetic yellow iron oxide. Labetalol HCl Tablets, USP 300 mg also contain FD & C blue No. 2 aluminum lake.